Table 2.
Clinical pathological and follow-up data from patients.
| Pathologic variables | No. of patients (%) |
|---|---|
| TNM stage | 132 |
| Stage I | 94 (71.2%) |
| Stage II | 23 (17.4%) |
| Stage III | 11 (8.3%) |
| Stage IV | 4 (3.1%) |
| HCC differentiation | 132 |
| WD | 33 (25.0%) |
| MD | 66 (50.0%) |
| PD | 33 (25.0%) |
| Number of tumors | 132 |
| Multiple tumors | 31 (23.5%) |
| Solitary tumor | 101 (76.5%) |
| Vascular invasion | 132 |
| Yes | 21 (15.9%) |
| No | 111 (84.1%) |
| Lymph node metastasis | 132 |
| Yes | 4 (3.0%) |
| No | 128 (97.0%) |
| Extrahepatic metastasis | 132 |
| Yes | 3 (2.3%) |
| No | 129 (97.7%) |
| Postoperative recurrence | 132 |
| Yes | 88 (66.7%) |
| No | 44 (33.3%) |
| Cancer related death | 74 (56.06%) |
| Survival | 53 (40.2%) |
| TMUB1 expression status | |
| 0 | 6 (4.5%) |
| 1+ | 47 (35.6%) |
| 2+ | 43 (32.6%) |
| 3+ | 36 (27.3%) |
HCC – hepatocellular carcinoma; WD – well differentiated; MD – moderately differentiated; PD – poorly differentiated; TMUB1 – transmembrane and ubiquitin-like domain-containing protein 1.